Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmaceutics
Egile Nagusiak: Berdugo, Marianne, Delaunay, Kimberley, Lebon, Cécile, Naud, Marie-Christine, Radet, Lolita, Zennaro, Léa, Picard, Emilie, Daruich, Alejandra, Beltrand, Jacques, Kermorvant-Duchemin, Elsa, Polak, Michel, Crisanti, Patricia, Behar-Cohen, Francine F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8308933/
https://ncbi.nlm.nih.gov/pubmed/34371786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13071095
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak